Cargando…
New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib
Until recently, few treatment options existed for the treatment of squamous cell carcinoma (SqCC) of the lung, especially in the second-line setting following platinum-based chemotherapy. Accordingly, outcomes in this subtype of non-small-cell lung cancer (NSCLC) were generally poor. In this context...
Autor principal: | Hirsh, Vera |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5436789/ https://www.ncbi.nlm.nih.gov/pubmed/28546756 http://dx.doi.org/10.2147/OTT.S104177 |
Ejemplares similares
-
Development of treatment options for Chinese patients with advanced squamous cell lung cancer: focus on afatinib
por: Lu, Shun
Publicado: (2019) -
Role of afatinib in the treatment of advanced lung squamous cell carcinoma
por: Vavalà, Tiziana
Publicado: (2017) -
Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib
por: Hirsh, Vera
Publicado: (2015) -
Advanced Squamous Cell Carcinoma of the Lung: Current Treatment Approaches and the Role of Afatinib
por: Santos, Edgardo S, et al.
Publicado: (2020) -
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treatment of Metastatic Non-Small Cell Lung Cancer, with a Focus on Afatinib
por: Morin-Ben Abdallah, Sami, et al.
Publicado: (2017)